Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.

checkorphan
Learn more about:
Tardive dyskinesia
Related Clinical Trial
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects Reduction of Demoralization After Treatment of TD With Valbenazine Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Dysport for the Treatment of OMD Validation of the Implantation of a New Electrode for the Treatment of Dystonia Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia D-Serine Treatment For Tardive Dyskinesia Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Levetiracetam Treatment of Tardive Dyskinesia The Assessment of Movement Disorders Utilizing Live Two-Way Video Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents Xenazine in Late Dyskinetic Syndrome With Neuroleptics Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia Melatonin Treatment for Tardive Dyskinesia in Schizophrenia Extract of Ginkgo Biloba and Tardive Dyskinesia Aim to Reduce Movements in Tardive Dyskinesia Reducing Involuntary Movements in Tardive Dyskinesia A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Pyridoxal Kinase Activity in Tardive Dyskinesia Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Piracetam for Treatment Tardive Dyskinesia Treatment of Tardive Dyskinesia With Galantamine Tardive Dyskinesia and Cognitive Function Safety and Efficacy of Pyridoxal 5′ -Phosphate in the Treatment of Tardive Dyskinesia Addressing Involuntary Movements in Tardive Dyskinesia Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia

Brief Title

Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.

Official Title

Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.

Brief Summary

      The purpose of this study is to explore the therapeutic effect and mechanism of transcranial
      magnetic stimulation (rTMS) in the treatment of the tardive dyskinesia.

Detailed Description

      The study was a parallel control design trial for 2 weeks. Patients with schizophrenia were
      treated with 10-Hz rTMS on left motor cortex (added to the ongoing treatment). Clinical
      symptoms and MEP were assessment before and after rTMS treatment.

Study Type

Interventional

Primary Outcome

Change from baseline in motor evoked potential(MEP)

Secondary Outcome

 Change from baseline in cortical silent period

Condition

Tardive Dyskinesia

Intervention

Repetitive Transcranial Magnetic Stimulation

Study Arms / Comparison Groups

 tardive dyskinesia group
Description:  tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex（M1）.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Device

Estimated Enrollment

60

Start Date

September 2016

Completion Date

December 2018

Primary Completion Date

December 2018

Eligibility Criteria

        Inclusion Criteria:

          -  The diagnosis of schizophrenia according to DSM-IV；

          -  At least two item of Abnormal Involuntary Movement Scale（AIMS） must be 2 points or
             higher

          -  these symptoms are not from Parkinson，tourette's syndrome,huntington disease

          -  Signed an informed consent

        Exclusion Criteria:

          -  rTMS contraindications: intracranial metal substance, with heart pacemakers and
             cochlear implants, intracranial pressure

          -  patients to be diagnosed according to DSM-IV for substance abused, development delayed

          -  current treatment with anticonvulsant acting drugs such as anticonvulsants,
             benzodiazepines

          -  Acute risk of suicide and impulse

          -  history of epileptic seizures or the presence of epileptic activity documented on the
             basis of EEG

          -  pregnant and lactant women

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, +86 21 64387250-73775, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations

NCT ID

NCT02840760

Organization ID

15ZR1435600

Responsible Party

Sponsor

Study Sponsor

Shanghai Mental Health Center

Study Sponsor

, ,

Verification Date

June 2017